|
1
|
Naik RG, Kattige SL, Bhat SV, Alreja B, de
Souza NJ and Rupp RH: An antiinflammatory cum immunomodulatory
piperidinylbenzopyranone from dysoxylum binectariferum: isolation,
structure and total synthesis. Tetrahedron. 44:2081–2086. 1988.
View Article : Google Scholar
|
|
2
|
Newcomb EW, Tamasdan C, Entzminger Y, et
al: Flavopiridol induces mitochondrial-mediated apoptosis in murine
glioma GL261 cells via release of cytochrome c and apoptosis
inducing factor. Cell Cycle. 2:243–250. 2003. View Article : Google Scholar
|
|
3
|
Grant S and Dent P: Gene profiling and the
cyclin-dependent kinase inhibitor flavopiridol: what’s in a name?
Mol Cancer Ther. 3:873–875. 2004.
|
|
4
|
König A, Schwartz GK, Mohammad RM,
Al-Katib A and Gabrilove JL: The novel cyclin-dependent kinase
inhibitor flavopiridol downregulates Bcl-2 and induces growth
arrest and apoptosis in chronic B-cell leukemia lines. Blood.
90:4307–4312. 1997.
|
|
5
|
Hooijberg JH, Broxterman HJ, Scheffer GL,
et al: Potent interaction of flavopiridol with MRP1. Br J Cancer.
81:269–276. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cimica V, Smith ME, Zhang Z, Mathur D,
Mani S and Kalpana GV: Potent inhibition of rhabdoid tumor cells by
combination of flavopiridol and 4OH-tamoxifen. BMC Cancer.
10:6342010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen R, Keating MJ, Gandhi V and Plunkett
W: Transcription inhibition by flavopiridol: mechanism of chronic
lymphocytic leukemia cell death. Blood. 106:2513–2519. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Senderowicz AM: Flavopiridol: the first
cyclin-dependent kinase inhibitor in human clinical trials. Invest
New Drugs. 17:313–320. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stadler WM, Vogelzang NJ, Amato R, et al:
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in
metastatic renal cancer: a University of Chicago Phase II
Consortium study. J Clin Oncol. 18:371–375. 2000.PubMed/NCBI
|
|
10
|
Budak-Alpdogan T, Chen B, Warrier A,
Medina DJ, Moore D and Bertino JR: Retinoblastoma tumor suppressor
gene expression determines the response to sequential flavopiridol
and doxorubicin treatment in small-cell lung carcinoma. Clin Cancer
Res. 15:1232–1240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meacham CE and Morrison SJ: Tumour
heterogeneity and cancer cell plasticity. Nature. 501:328–337.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kreso A and Dick JE: Evolution of the
cancer stem cell model. Cell Stem Cell. 14:275–291. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
La Porta CA: Mechanism of drug sensitivity
and resistance in melanoma. Curr Cancer Drug Targets. 9:391–397.
2009.PubMed/NCBI
|
|
14
|
Goksel G, Bilir A, Uslu R, Akbulut H,
Guven U and Oktem G: WNT1 gene expression alters in heterogeneous
population of prostate cancer cells; decreased expression pattern
observed in CD133+/CD44+ prostate cancer stem
cell spheroids. J BUON. 19:207–214. 2014.PubMed/NCBI
|
|
15
|
Oktem G, Bilir A, Uslu R, Inan SV, Demiray
SB, Atmaca H, Ayla S, Sercan O and Uysal A: Expression profiling of
stem cell signaling alters with spheroid formation in
CD133high/CD44high prostate cancer stem
cells. Oncol Lett. 7:2103–2109. 2014.PubMed/NCBI
|
|
16
|
Ayla S, Bilir A, Soner BC, Yilmaz-Dilsiz
O, Erguven M and Oktem G: Notch signaling-related therapeutic
strategies with novel drugs in neuroblastoma spheroids. J Pediatr
Hematol Oncol. 36:37–44. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wirger A, Perabo FG, Burgemeister S, et
al: Flavopiridol, an inhibitor of cyclin-dependent kinases, induces
growth inhibition and apoptosis in bladder cancer cells in vitro
and in vivo. Anticancer Res. 25:4341–4347. 2005.PubMed/NCBI
|
|
18
|
Chien M, Astumian M, Liebowitz D,
Rinker-Schaeffer C and Stadler WM: In vitro evaluation of
flavopiridol, a novel cell cycle inhibitor, in bladder cancer.
Cancer Chemother Pharmacol. 44:81–87. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nelson DM, Joseph B, Hillion J, Segal J,
Karp JE and Resar LM: Flavopiridol induces BCL-2 expression and
represses oncogenic transcription factors in leukemic blasts from
adults with refractory acute myeloid leukemia. Leuk Lymphoma.
52:1999–2006. 2011. View Article : Google Scholar
|
|
20
|
Smith ME, Cimica V, Chinni S, Challagulla
K, Mani S and Kalpana GV: Rhabdoid tumor growth is inhibited by
flavopiridol. Clin Cancer Res. 14:523–532. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mayer F, Mueller S, Malenke E, Kuczyk M,
Hartmann JT and Bokemeyer C: Induction of apoptosis by flavopiridol
unrelated to cell cycle arrest in germ cell tumour derived cell
lines. Invest New Drugs. 23:205–211. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Taniai M, Grambihler A, Higuchi H, et al:
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing
ligand resistance in human cholangiocarcinoma cells. Cancer Res.
64:3517–3524. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Decker RH, Dai Y and Grant S: The
cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in
human leukemia cells (U937) through the mitochondrial rather than
the receptor-mediated pathway. Cell Death Differ. 8:715–724. 2001.
View Article : Google Scholar
|
|
24
|
Villela L and Bolaños-Meade J: Acute
myeloid leukaemia: optimal management and recent developments.
Drugs. 71:1537–1550. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lamb R, Lehn S, Rogerson L, Clarke RB and
Landberg G: Cell cycle regulators cyclin D1 and CDK4/6 have
estrogen receptor-dependent divergent functions in breast cancer
migration and stem cell-like activity. Cell Cycle. 12:2384–2394.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yao Y, Shi J, Zhang Z, Zhang F, Ma R and
Zhao Y: The radiation-sensitizing effect of flavopiridol in the
esophageal cancer cell line Eca109. Oncol Lett. 5:1872–1876.
2013.PubMed/NCBI
|
|
27
|
Chao SH, Fujinaga K, Marion JE, et al:
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol
Chem. 275:28345–28348. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carlson B, Lahusen T, Singh S, et al:
Down-regulation of cyclin D1 by transcriptional repression in MCF-7
human breast carcinoma cells induced by flavopiridol. Cancer Res.
59:4634–4641. 1999.PubMed/NCBI
|
|
29
|
Chao SH and Price DH: Flavopiridol
inactivates P-TEFb and blocks most RNA polymerase II transcription
in vivo. J Biol Chem. 276:31793–31799. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
de Azevedo WF Jr, Canduri F and da
Silveira NJ: Structural basis for inhibition of cyclin-dependent
kinase 9 by flavopiridol. Biochem Biophys Res Commun. 293:566–571.
2002.PubMed/NCBI
|
